A5006076534- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Cancer, Lipids, and Metabolism
- Viral-associated cancers and disorders
- Hepatitis B Virus Studies
- Liver physiology and pathology
- Lung Cancer Research Studies
- Hepatitis C virus research
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatic and Hepatic Oncology Research
- Liver Disease and Transplantation
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- Nanoplatforms for cancer theranostics
- Immune cells in cancer
- Hemodynamic Monitoring and Therapy
- Face and Expression Recognition
- Radiopharmaceutical Chemistry and Applications
- Electricity Theft Detection Techniques
- Cancer Genomics and Diagnostics
- Text and Document Classification Technologies
Sun Yat-sen University Cancer Center
2019-2025
Sun Yat-sen University
2019-2025
State Key Laboratory of Oncology in South China
2020-2025
Wuhan University
2011-2012
Background: Lenvatinib plus Programmed Death-1 (PD-1) inhibitors (LEN-P) have been recommended in China for patients with advanced hepatocellular carcinoma (HCC). However, they provide limited survival benefits to extrahepatic metastases. We aimed investigate whether combining hepatic arterial infusion chemotherapy (HAIC) LEN-P could improve its efficacy. Materials and Methods: This multi-center cohort study included HCC metastases who received HAIC combined (HAIC-LEN-P group, n=127) or...
In patients with small late-recurrence hepatocellular carcinoma, combined transarterial chemoembolization radiofrequency ablation did not result in better survival outcomes compared surgical resection alone but could be a safer option.
PURPOSE To assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC). METHODS In this trial, patients with HCC (single lesion ≤5 cm) were randomly assigned to receive either SBRT or RFA. The primary end point was local progression-free survival (LPFS), secondary points (PFS), overall (OS), control rate, safety. RESULTS Between August 2019 April 2022, 166 (n = 83) RFA groups. After a...
Peritumoral hepatocytes are critical components of the liver cancer microenvironment, However, role peritumoral in local tumor immune interface and underlying molecular mechanisms have not been elucidated. YTHDF2, an RNA N
Abstract Background Patients with hepatocellular carcinoma (HCC) undergoing surgical resection still have a high 5‐year recurrence rate (~ 60%). With the development of laparoscopic hepatectomy (LH), few studies compared efficacy between LH and traditional approach on HCC. The objective this study was to establish nomogram evaluate risk in HCC patients who underwent LH. Methods clinical data 432 patients, pathologically diagnosed HCC, as initial treatment had margin > 1 cm were collected....
Inflammatory response is related to tumor progression and patient survival. We aimed clarify the prognostic value of inflammation-based scores in intrahepatic cholangiocarcinoma (ICC) patients receiving anti-PD1 therapy.A total 73 who received anti-PD-1 therapy from February 2019 2021 were included study. Representative scores, including C-reactive protein (CRP), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte (NLR), lymphocyte-to-CRP (LCR), lymphocyte-to-monocyte (LMR),...
Radiofrequency ablation (RFA) is a widely used therapy for hepatocellular carcinoma (HCC). However, in cases of insufficient RFA (iRFA), nonlethal temperatures the transition zone increase risk postoperative relapse. The pathological analysis HCC tissues shows that iRFA-induced upregulation myeloid-derived suppressor cells (MDSCs) residual tumors critical recurrence. Furthermore, this study demonstrates, first time, combining MDSCs suppression strategy during iRFA can unexpectedly lead to...
Background Hepatitis B virus (HBV) reactivation is a common complication in hepatocellular carcinoma (HCC) patients treated with chemotherapy or immunotherapy. This study aimed to evaluate the risk of HBV and its effect on survival HCC HAIC lenvatinib plus PD1s. Methods We retrospectively collected data 213 HBV-related who underwent PD1s treatment between June 2019 2022 at Sun Yat-sen University, China. The primary outcome was reactivation. secondary outcomes were overall (OS),...
Abstract With the rise of anti‐vascular endothelial growth factor antibody and programmed cell death‐ligand 1 (PD‐L1) regimens, particularly bevacizumab atezolizumab, as first‐line treatments for advanced hepatocellular carcinoma (HCC), there is a need to explore PD‐L1 death inhibitors in combination therapies unresectable HCC (uHCC). Integrating systemic with locoregional approaches also emerging potent strategy. This study compares outcomes atezolizumab (PD‐L1 inhibitor) sintilimab...
Background: Systemic chemotherapy (SC) remains the only first-line treatment for unresectable intrahepatic cholangiocarcinoma (iCCA). Hepatic arterial infusion (HAIC) has been recently proven to be effective in managing hepatocellular carcinoma (HCC). Hence, our study aims investigate safety and efficacy of HAIC treating iCCA patients. Methods: We reviewed 146 patients with who had received or SC between March 2016 2022 a retrospective manner. Outcomes were compared groups. Results: There 75...
Alpha-fetoprotein (AFP) has been established as a biomarker for hepatocellular carcinoma (HCC); however, whether its dynamic changes could predict the response to systemic therapy remains elusive. This study explored AFP trajectory and association with survival in patients received bevacizumab plus immunotherapy. We retrospectively enrolled 536 HCC immunotherapy between February 2021 2023. Patients were divided into two groups according values before treatment (400 ng/ml). Dynamic of fitted...
Background: High rate of tumor recurrence jeopardized the long-term survival hepatocellular carcinoma (HCC) patients with complete response to transarterial chemoembolization (TACE). This study aims evaluate benefit liver resection (LR) following TACE for intermediate-stage HCC. Methods: A total 281 HCC followed by persistent observation (TACE group) or LR (TLR from January 01, 2011 December 31, 2021 three institutions in China were included. Overall (OS) and disease-free (DFS) compared...
The importance of alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) in hepatocellular carcinoma (HCC) has been studied extensively Japan, where hepatitis C virus is the predominant aetiology HCC. clinical profiles HCC regarding state AFP DCP a B epidemic area have not comprehensively investigated, value these tumour markers evaluating response to treatment detection recurrence yet be determined. A total 4792 patients treated our centre were continuously analysed accessible data...